Table 3. Ongoing trials studying the anticoagulation treatment in patients with AF and HF, who underwent TAVI.

Study Name	Duration	Type	Expected population (participants)	AF patients	Comparators	Primary endpoint
¹Described adverse event composite includes all-cause death, MI, ischemic stroke, systemic embolic events (SEE), valve thrombosis, and major bleeding per definition of the International Society on Thrombosis and Hemostasis. ²The composite of all-cause death, TIA/stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep venous thrombosis, systemic embolism, life-threatening, disabling or major bleeding, according to the Valve Academic Research Consortium definitions. ³Death from any cause, myocardial infarction, stroke all causes, valve thrombosis and hemorrhage ≥ 2 as defined by the VARC 2 (Valve Academic Research Consortium scale). AF: atrial fibrillation; MI: myocardial infarction; NA: not available; NOAC: non-vitamin K oral anticoagulants; RCT: randomized-control trial; SEE: systemic embolic events; TAVI: transcatheter aortic valve implantation.
ENVISAGE-TAVI AF^[76]	2017−2021	RCT	1,400	All	Edoxaban vs. Warfarin	Number of participants experiencing the described adverse event composite within 36 months.¹
ATLANTIS^[77]	2016−2020	RCT	1509	Stratum 1 (patients requiring lifetime OAC)	Apixaban vs. Warfarin	Composite Primary Endpoint in 12 months.²
AVATAR	2017−2020	RCT	170	NA	NOAC vs. NOAC + aspirin	Composite Primary Endpoint in 12 months.³